Welcome to the Radboudumc what are you looking for?
Nielka van Erp's research group aims to optimize anticancer treatment in oncology patients by recognizing and addressing interindividual differences and by developing approaches to keep the drugs available for all patients suffering from cancer.
Bart van den Bemt's research group is a (inter)nationally recognized group on adequate medication use, medication adherence, medication waste and (cost-)effective pharmacotherapy.
Roger Brüggemann's and Nynke Jager's research group investigates the pharmacokinetics and dynamics of antimicrobial agents. Research ranges from in vitro experiments to clinical trials in special patient populations. The main aim is to define the optimal dose for each individual patient.
Rob Aarnoutse's research group investigates the pharmacology of existing and new drugs for tuberculosis, using a translational approach that extends from molecular pharmacology to clinical pharmacology studies and to clinical trials, supported by advanced laboratory and modeling techniques.
David Burger's group investigates the pharmacology of antiviral drugs for the treatment of HIV and hepatitis C in special patient population such as pregnant women, children and hepatically impaired patients. We also study drug-drug interactions and the impact on exposure of new drug-formulations.
Daniele Tauriello's, Henk Verheul's, Nielka van Erp's and Iris Nagtegaal's research group is a cross-disciplinary research collaboration of four Radboudumc groups, with the aim of advancing clinical translation for colorectal cancer.
Reinout van Crevel's research group integrates patient studies and laboratory sciences to understand the biology of tuberculosis (TB) transmission, infection and disease, including its severest form: meningitis.
This website uses cookies. Read more about cookies.